Calimmune

Key RNAi Drugs in the Clinic

Premium

NEW YORK (GenomeWeb) – With more interest from industry and investors than ever before, the RNAi therapeutics field has a record number of drug candidates in human testing for indications ranging from viral disease to cancer to skin disorders.

NEW YORK (GenomeWeb) – CalImmune this week announced that it has been cleared by the US Food and Drug Administration to treat a second cohort of patients in a clinical trial of its expressed RNAi-based treatment for HIV infection.

Calimmune has become the latest RNAi drug developer to move into the clinic, recently initiating a phase I/II trial of its HIV therapy Cal-1.

Two years after the US Patent and Trademark Office reinstated its core patent, Australia's Benitec Biopharma has once again set its sights on finding licensees for its expressed RNAi intellectual property.

Title: Triggered RNAi
Patent Number: 8,241,854
Filed: May 22, 2009
Lead Inventor: Peng Yin, California Institute of Technology

Benitec Biopharma said this week that it has non-exclusively licensed its expressed RNAi technology to Calimmune for use in developing an RNAi-based HIV/AIDS treatment.

The New York Times and ProPublica look into the close relationship between a startup and Memorial Sloan Kettering Cancer Center.

Yahoo News reports millions of dollars are being transferred from NIH, CDC, and other programs to pay for the housing of detained undocumented immigrant children.

In Science this week: in vitro generation of human reproductive cells, and more.

Researchers gave a handful of octopuses MDMA to find that they too act more social on the drug, Gizmodo reports.